Sonal S. Noticewala

Sonal S. Noticewala

Auto-generated profile, based on publicly available information

Sonal S. Noticewala

Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
JGJill A. Gallaher
Jill A. Gallaher
SMSusan C Massey
Susan C Massey
AHAndrea Hawkins-Daarud
Andrea Hawkins-Daarud
SNSonal S Noticewala
Sonal S Noticewala
RRRussell Rockne
Russell Rockne
Alexander AndersonAlexander Anderson
Alexander Anderson
Glioblastomas are aggressive primary brain tumors known for their inter- and intratumor heterogeneity. This disease is uniformly fatal, with intratumor heterogeneity the major reason for treatment failure and recurrence. Just like the nature vs nurture debate, heterogeneity can arise from intrinsic or environmental influences. Whilst it is impossible to clinically separate observed behavior of cells from their environmental context, using a mathematical framework combined with multiscale data gives us insight into the relative roles of variation from different sources. To better understand the implications of intratumor heterogeneity on therapeutic outcomes, we created a hybrid agent-based mathematical model that captures both the overall tumor kinetics and the individual cellular behavior. We track single cells as agents, cell density on a coarser scale, and growth factor diffusion and dynamics on a finer scale over time and space. Our model parameters were fit utilizing serial MRI imaging and cell tracking data from ex vivo tissue slices acquired from a growth-factor driven glioblastoma murine model. When fitting our model to serial imaging only, there was a spectrum of equally-good parameter fits corresponding to a wide range of phenotypic behaviors. When fitting our model using imaging and cell scale data, we determined that environmental heterogeneity alone is insufficient to match the single cell data, and intrinsic heterogeneity is required to fully capture the migration behavior. The wide spectrum of in silico tumors also had a wide variety of responses to an application of an anti-proliferative treatment. Recurrent tumors were generally less proliferative than pre-treatment tumors as measured via the model simulations and validated from human GBM patient histology. Further, we found that all tumors continued to grow with an anti-migratory treatment alone, but the anti-proliferative/anti-migratory combination generally showed improvement over an anti-proliferative treatment alone. Together our results emphasize the need to better understand the underlying phenotypes and tumor heterogeneity present in a tumor when designing therapeutic regimens. Glioblastoma, the most common primary brain tumor, is an aggressive and difficult to treat cancer. A key reason is that the tumors can be very heterogeneous, consisting of many different mutants driving distinct cell behaviors. We believe that treatments for this disease could be significantly improved by understanding and quantifying the functional impact of heterogeneity within the tumor. From a clinical standpoint, the larger tissue-scale dynamics, like growth rate, can be informed from serial MRI imaging, while the cell-scale heterogeneity, can be informed by analysis of biopsies. In this work, we combined information from both scales using a mathematical framework and multiscale data from an animal model of glioblastoma. We found that a wide range of potential tumor compositions matched imaging data alone, as a result the model predicts a wide variety of responses to treatment. Using both imaging and cell-scale data narrowed the range of possible tumor compositions and better predicted responses to treatment. The mathematical model also predicted that while targeting migration alone did not slow tumor growth (in fact it drove a more proliferative tumor), an anti-proliferative/anti-migratory treatment combination improved treatment response.

10 October 2013 in Case Reports in Neurological Medicine
Verified
Journal Article
Open access
PDF file
TWTeresa J. Wojtasiewicz
Teresa J. Wojtasiewicz
ADAndrew F. Ducruet
Andrew F. Ducruet
SNSonal S. Noticewala
Sonal S. Noticewala
PCPeter Canoll
Peter Canoll
GMGuy M. McKhann
Guy M. McKhann
We report a case of a patient who developed glioblastoma in the territory of a previous infarction. Two years after an ischemic stroke, the patient presented with a cystic, necrotic, and heterogeneously enhancing mass. Open biopsy and debulking of the mass with histological analysis revealed the mass to be glioblastoma. Though several cases of posttraumatic GBM have been reported, this is the first proposed case of GBM after an ischemic stroke. From this case, we suggest that the ischemic stroke, like other forms of cortical injury, may predispose to glioblastoma formation.

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
SNS.S. Noticewala
S.S. Noticewala
CWC.W. Williamson
C.W. Williamson
JMJ.D. Murphy
J.D. Murphy

26 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJill A. Gallaher
Jill A. Gallaher
SMSusan C. Massey
Susan C. Massey
AHAndrea Hawkins-Daarud
Andrea Hawkins-Daarud
SNSonal S. Noticewala
Sonal S. Noticewala
RRRussell Rockne
Russell Rockne
Alexander AndersonAlexander Anderson
Alexander Anderson
Glioblastomas are aggressive primary brain tumors known for their inter- and intratumor heterogeneity. This disease is uniformly fatal, with intratumor heterogeneity the major reason for treatment failure and recurrence. Just like the nature vs nurture debate, heterogeneity can arise from heritable or environmental influences. Whilst it is impossible to clinically separate observed behavior of cells from their environmental context, using a mathematical framework combined with multiscale data gives us insight into the relative roles of variation from inherited and environmental sources. To better understand the implications of intratumor heterogeneity on therapeutic outcomes, we created a hybrid agent-based mathematical model that captures both the overall tumor kinetics and the individual cellular behavior. We track single cells as agents, cell density on a coarser scale, and growth factor diffusion and dynamics on a finer scale over time and space. Our model parameters were fit utilizing serial MRI imaging and cell tracking data from ex vivo tissue slices acquired from a growth-factor driven glioblastoma murine model. When fitting our model to serial imaging only, there was a spectrum of equally-good parameter fits corresponding to a wide range of phenotypic behaviors. This wide spectrum of in silico tumors also had a wide variety of responses to an application of an antiproliferative treatment. Recurrent tumors were generally less proliferative than pre-treatment tumors as measured via the model simulations and validated from human GBM patient histology. When fitting our model using imaging and cell scale data, we determined that heritable heterogeneity is required to capture the observed migration behavior. Further, we found that all tumors increased in size after an anti-migratory treatment, and some tumors were larger after a combination treatment than with an anti-proliferative treatment alone. Together our results emphasize the need to understand the underlying phenotypes and tumor heterogeneity in designing therapeutic regimens.